SPARTA Biodiscovery Analysis: $4M Raised
What is SPARTA Biodiscovery?
SPARTA® technology enables label-free, single-particle nanocharacterisation
Location
London, United Kingdom
Employees
11-50
Founded
2022
Product Features & Capabilities
- SPARTA® analytical service
- SPARTA® benchtop instrument
Use Cases
Characterise single nanoparticles in drug delivery systems; Analyse viral vectors for gene therapy applications; Monitor real-time reactions in nanoparticle synthesis; Characterise exosomes for biomarker discovery; Perform high-throughput screening of synthetic nanoparticles
Other Considerations
Spin-out from Imperial College London; Patented technology; Available as analytical service and benchtop instrument; Compatible with exosomes and viral vectors; Real-time dynamic reaction monitoring capability; High-throughput, non-destructive analysis; No nanoparticle modification required
See something that needs updating? Suggest edits to this profile.